Gergely, Tamás G.
Drobni, Zsófia D.
Sayour, Nabil V.
Ferdinandy, Péter
Varga, Zoltán V.
Funding for this research was provided by:
Horizon 2020 (739593)
Magyar Tudományos Akadémia (LP-2021-14)
European Union (RRF-2.3.1-21-2022-00003)
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (2022-1.1.1-KK-2022-00005., ÚNKP-22-4-II-SE, ÚNKP-23-3-II-SE-42)
Semmelweis University
Article History
Received: 30 May 2024
Revised: 9 July 2024
Accepted: 10 July 2024
First Online: 17 July 2024
Declarations
:
: The authors declare no conflict of interest. Dr. Ferdinandy is the founder and CEO of Pharmahungary Group, a group of R&D companies.